Literature DB >> 24469257

Highlights of the 26th EANM 2013 congress in Lyon: new horizons and further.

Frank Bengel1, Rachele Bonfiglioli, Stefano Fanti.   

Abstract

The 26th European Association of Nuclear Medicine (EANM) annual congress was held in Lyon, France, under the chairmanship of Professor Dominique LeGuludec. The congress was attended by more than 5,200 participants, with about one-quarter coming from outside Europe. This review summarizes the major scientific contributions which were selected from the more than 1,700 submitted abstracts, and presented in the closing highlights session. They covered the diverse areas of nuclear medicine, with particular focus on oncology, cardiovascular science and neurology. Various innovations were reported regarding imaging methodology, physics, radiopharmaceuticals and chemistry. Novel radionuclide applications in both diagnosis and therapy were investigated and described, triggering strong interest from the many professionals involved. Significant progress has been demonstrated in the clinical use of existing nuclear medicine procedures, and a number of new applications are under development in preclinical and early clinical stages. The congress was a unique opportunity to get a thorough update on this research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469257     DOI: 10.1007/s00259-013-2665-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  3 in total

Review 1.  A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification.

Authors:  Pascaline Schollaert; Ralph Crott; Claude Bertrand; Lionel D'Hondt; Thierry Vander Borght; Bruno Krug
Journal:  J Gastrointest Surg       Date:  2014-03-18       Impact factor: 3.452

2.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

3.  [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.

Authors:  Shizuo Hatashita; Hidetomo Yamasaki; Yutaka Suzuki; Kumiko Tanaka; Daichi Wakebe; Hideki Hayakawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.